TruScreen Signs MOU with Hangzhou Dalton Bioscience

• Collaboration to expand TruScreen's HPV product portfolio
• DaltonBio's HPV DNA tests and self-sampling tests to be marketed under TruScreen brand
• Potential for DaltonBio to assist with TruScreen's AI-enabled cervical screening device

TruScreen Group Limited, a global leader in AI-enabled cervical cancer screening, has signed a non-binding Memorandum of Understanding (MOU) with Hangzhou Dalton Bioscience Limited (DaltonBio), a leading China-based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening. The collaboration aims to distribute and market a suite of DaltonBio's HPV-related In Vitro Diagnostics (IVD) products, including HPV DNA tests and self-sampling tests, through TruScreen's selected global distribution network under the TruScreen brand. This partnership will enhance access to innovative cervical cancer screening and detection solutions by leveraging the technology strengths of both companies. The proposed collaboration consists of two key stages: a short-term due diligence phase on DaltonBio's products, followed by a medium-to-long-term strategic alliance where TruScreen will be appointed a global distributor of DaltonBio's HPV-related IVD products (excluding the U.S. and Canada). Additionally, DaltonBio will explore opportunities to assist TruScreen's AI-enabled real-time cervical screening device within its distribution network, particularly in China and South America. This collaboration is a significant step forward in TruScreen's mission to provide accessible and innovative cervical cancer screening solutions worldwide, as DaltonBio's HPV screening tests complement TruScreen's AI-enabled technology.

TruScreen reported over 200,000 examinations performed with its device in the 2024 financial year. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia.

The collaboration with DaltonBio is expected to expand TruScreen's HPV product portfolio and strengthen its global position in the women's health sector. The companies will work towards formalizing a distribution agreement within three months.